Corvus Enterprise Value Over E B I T D A from 2010 to 2024
| CRVS Stock | USD 8.94 0.70 8.50% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (2.73) | Current Value (2.86) | Quarterly Volatility 247.89689242 |
Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.4 K, Interest Expense of 864.5 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.29. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.
Corvus | Enterprise Value Over E B I T D A |
Latest Corvus Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Corvus Pharmaceuticals over the last few years. It is Corvus Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corvus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Corvus Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (173.42) | |
| Geometric Mean | 13.95 | |
| Coefficient Of Variation | (142.95) | |
| Mean Deviation | 225.76 | |
| Median | (3.23) | |
| Standard Deviation | 247.90 | |
| Sample Variance | 61,453 | |
| Range | 512 | |
| R-Value | 0.82 | |
| Mean Square Error | 21,719 | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 45.43 | |
| Total Sum of Squares | 860,340 |
Corvus Enterprise Value Over E B I T D A History
About Corvus Pharmaceuticals Financial Statements
Corvus Pharmaceuticals shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Corvus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corvus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corvus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (2.73) | (2.86) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.